Basic Information
| LncRNA/CircRNA Name | PAPAS |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | gastric cancer |
| ICD-0-3 | C16 |
| Methods | qRT-PCR, Dual Luciferase Reporter Gene Assay |
| Sample | GC tissues,GC cell lines (AGS, BGC-823, SGC-7901, and HGC-27) and epithelial cells of the gastric mucosa (GES-1) |
| Expression Pattern | up-regulated |
| Function Description | PAPAS was upregulated in GC tissues and cell lines compared to controls. GC patients expressing a high level of PAPAS suffered worse prognosis relative to those with low level. The silence of PAPAS remarkably attenuated proliferative, migratory, and invasive abilities of HGC-27 cells. Overexpression of PAPAS in AGS cells obtained the opposite trends. MiRNA-188-5p was the direct target of PAPAS, which was negatively regulated by PAPAS. |
| Pubmed ID | 31858543 |
| Year | 2019 |
| Title | LncRNA PAPAS Aggravates the Progression of Gastric Cancer Through Regulating miRNA-188-5p |
External Links
| Links for PAPAS | GenBank HGNC NONCODE |
| Links for gastric cancer | OMIM COSMIC |